Although BCL2 family proteins are frequently expressed in most PTCL subtypes29, 30, 31, 32, the majority of the cell lines are relatively resistant to the BH3-mimetic drugs in clinical use obatoclax, ABT-737 and venetoclax (ABT-199) (Supplementary Fig. 5). This evidence concerns the gene BCL2 and mature T-cell and NK-cell non-Hodgkin lymphoma.